[1]张静琦,周晓洲,季惠翔,等.根治性前列腺癌切除术后首次血清PSA水平的影响因素分析[J].第三军医大学学报,2019,41(16):1590-1595.
 ZHANG Jingqi,ZHOU Xiaozhou,JI Huixiang,et al.Analysis of factors affecting first serum prostate specific antigen level after radical prostatectomy for prostate canc[J].J Third Mil Med Univ,2019,41(16):1590-1595.
点击复制

根治性前列腺癌切除术后首次血清PSA水平的影响因素分析
(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第16期
页码:
1590-1595
栏目:
临床医学
出版日期:
2019-08-30

文章信息/Info

Title:
Analysis of factors affecting first serum prostate specific antigen level after radical prostatectomy for prostate canc
作者:
张静琦周晓洲季惠翔郑霁陈志文
陆军军医大学(第三军医大学)第一附属医院泌尿外科,全军泌尿外科研究所
Author(s):
ZHANG Jingqi ZHOU Xiaozhou JI Huixiang ZHENG Ji CHEN Zhiwen
Institute of Urology, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China
 
关键词:
根治性前列腺癌切除术前列腺癌生化复发Logistic回归分析
Keywords:
radical prostatectomy prostate cancer biochemical recurrence Logistic regression analysis
分类号:
R181.23;R446.62;R737.25
文献标志码:
A
摘要:
目的 分析影响根治性前列腺癌切除术(radical prostatectomy,RP)后首次血清前列腺特异性抗原(prostate specific antigen,PSA)水平的因素。方法 回顾性收集2014年1月至2018年5月本科行RP的251例患者的临床病理资料,按照术后6~8周首次血清PSA值是否达到生化复发水平,以0.2 ng/mL为分界点将患者分为PSA <0.2 ng/mL组和PSA≥0.2 ng/mL组,针对两组患者数据进行单因素分析及多因素Logistic回归分析,筛选出影响RP后首次PSA水平的因素。结果 ①251例前列腺癌患者:两组患者在BMI、术前有无电切、术前PSA、术后Gleason评分、病理T分期、有无淋巴结清扫、淋巴结清扫数量差异均有统计学意义(P<0.05);多因素Logistic回归分析结果表明BMI、术前PSA、术后Gleason评分、病理T分期为影响术后首次血清PSA水平的独立危险因素;②153例淋巴结清扫的前列腺癌患者:两组在BMI、术前PSA、术后Gleason评分、病理T分期、淋巴结是否阳性、阳性淋巴结数量差异均有统计学意义(P<0.05);多因素Logistic回归分析结果表明术前PSA、淋巴结阳性为影响术后首次血清PSA水平的独立危险因素。结论 BMI、术前PSA、术后Gleason评分、病理T分期是影响前列腺癌患者术后首次血清PSA水平的独立危险因素;术前PSA和淋巴结阳性是影响淋巴结清扫的前列腺癌患者术后首次血清PSA水平的独立危险因素。
 
Abstract:

Objective To analyze the factors affecting postoperative first serum prostate specific antigen (PSA) level at 6 weeks in patients receiving radical prostatectomy (RP) for prostate cancer. MethodsThe clinicopathological data were collected retrospectively from 251 patients undergoing RP for prostate cancer in our department between January, 2014 and May, 2018. According to postoperative first serum PSA levels at 6-8 weeks for assessing biochemical recurrence (with 0.2 ng/mL as the cut-off PSA level), the patients were divided into PSA<0.2 ng/mL group and PSA≥0.2 ng/mL group, and univariate analysis and multivariate Logistic regression analysis was performed to identify the factors affecting first serum PSA level after RP. ResultsThe two groups of patients with prostate cancer showed significant differences in BMI, history of preoperative electric resection, preoperative PSA level, postoperative Gleason score, pathological T staging, lymph node dissection, and the number of dissected lymph nodes (P<0.05). The results of multivariate Logistic regression analysis showed that BMI, preoperative PSA level, postoperative Gleason score and pathological T staging were all independent risk factors affecting postoperative first serum PSA level. In the 153 patients with lymph node dissection, BMI, preoperative PSA level, postoperative Gleason score, pathological T staging, lymph node positivity and the number of positive lymph nodes differed significantly between the patients with postoperative PSA level <0.2 ng/mL at 6 weeks and those with higher PSA levels (P<0.05). Multivariate Logistic regression analysis showed that preoperative PSA level and lymph node positivity were independent risk factors that affected the postoperative first serum PSA level. ConclusionBMI, preoperative PSA level, postoperative Gleason score and pathologic T staging are all independent risk factors affecting the postoperative  first serum PSA level in prostate cancer patients; In patients with lymph node dissection, preoperative PSA level and lymph node positivity are independent risk factors affecting the postoperative  first serum PSA level.

参考文献/References:

[1]CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. Cancer J Clin, 2016, 66(2): 115-132. DOI:10.3322/caac.21338.
[2]叶定伟, 朱耀. 中国前列腺癌的流行病学概述和启示[J]. 中华外科杂志, 2015, 53(4): 249-252. DOI: 10.3760/cma.j.issn.0529-5815.2015.04.003.
YE D W, ZHU Y. Epidemiology of prostate cancer in China: an overview and clinical implication[J]. Chin J Surg, 2015, 53(4): 249-252.DOI:10.3760/cma.j.issn.0529-5815.2015.04.003.
[3]马春光, 叶定伟, 李长岭, 等. 前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J]. 中华外科杂志, 2008, 46(12): 921-925. DOI: 10.3321/j.issn:0529-5815.2008.12.012.
MA C G, YE D W, LI C L, et al. Epidemiology of prostate cancer from three centers and analysis of the first-fine hormonal therapy for the advanced disease[J]. Chin J Surg, 2008, 46(12): 921-925. DOI: 10.3321/j.issn:0529-5815.2008.12.012. 
[4]BRAWLEY O W, GANSLER T. Introducing the 2010 American cancer society prostate cancer screening guideline[J]. Cancer J Clin, 2010, 60(2): 68-69. DOI: 10.3322/caac.20067.
[5]MOHLER J L, ARMSTRONG A J, BAHNSON R R, et al. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: prostate cancer (Version 1.2017) [EB/OL]. [2016-12-16]. http://www.nccn.org/patients.
[6]中国抗癌协会泌尿男生殖系肿瘤专业委员会微创学组. 中国前列腺癌外科治疗专家共识[J]. 中华外科杂志, 2017, 55(10): 721-724.DOI: 10.3760/cma.j.issn.0529-5815.2017.10.001.
Minimally Invasive Surgery Group of Chinese Anti Cancer Association Genitourinary Oncology Committee. Consensus of Chinese experts on prostate neoplasms surgical treatment[J]. Chin J Surg, 2017, 55(10): 721-724. DOI: 10.3760/cma.j.issn. 0529-5815.2017.10. 001.
[7]CAO Y, MA J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: A systematic review and meta-analysis[J]. Cancer Prev Res (Phila), 2011, 4(4): 486-501. DOI: 10.1158/1940-6207.CAPR-10-0229. 
[8]MLLER H, ROSWALL N, VAN HEMELRIJCK M, et al. Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark[J]. Int J Cancer, 2015, 136(8): 1940-1947. DOI: 10.1002/ijc.29238. 
[9]VIDAL A C, HOWARD L E, SUN S X, et al. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH)database[J]. Prostate Cancer Prostatic Dis, 2017, 20(1): 72-78. DOI: 10.1038/pcan.2016.47. 
[10]BAI P D, HU M B, XU H, et al. Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: A retrospective cohort study and meta-analysis[J]. World J Surg Oncol, 2015, 13: 311. DOI: 10.1186/s12957-015-0725-0. 
[11]THOMPSON R H, BLUTE M L, SLEZAK J M, et al. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?[J]. J Urol, 2007, 178(2): 459-463; discussion 463. DOI: 10.1016/j.juro.2007.03.124. 
[12]RITCH C R, YOU C C, MAY A T, et al. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer[J]. Urology, 2014, 83(6): 1309-1315. DOI: 10.1016/j.urology.2014.02.023. 
[13]BARRY DELONGCHAMPS N, PEYROMAURE M, KPATCHA F, et al. PT3N0 prostate cancer treated with radical prostatectomy as sole treatment: Oncological results and predictive factors of recurrence[J].Prog Urol, 2012, 22(2): 100-105. DOI: 10.1016/j.purol.2011.08.041. 
[14]戴波, 常坤, 孔蕴毅, 等. 根治性前列腺切除术后患者生化复发的危险因素分析[J]. 中华外科杂志, 2015, 53(4): 261-265. DOI: 10.3760/cma.j.issn.0529-5815.2015.04.006.
DAI B, CHANG K, KONG Y Y, et al. Analysis of biochemical recurrence following radical prostatectomy[J]. Chin J Surg, 2015, 53(4): 261-265. DOI: 10.3760/cma.j.issn. 0529-5815.2015.04.006.
[15]DIAZ M, PEABODY J O, KAPOOR V, et al. Oncologic outcomes at 10 years following robotic radical prostatectomy[J].Eur Urol, 2015, 67(6): 1168-1176. DOI: 10.1016/j.eururo.2014.06.025. 
 

相似文献/References:

[1]刁鑫伟,叶明福,谢启超,等.二氢睾酮对前列腺癌LNcap和PC-3细胞株EGFR mRNA表达的影响[J].第三军医大学学报,2005,27(16):1690.
[2]王家武,姜庆,樊晓栋.新辅助内分泌联合治疗与单纯根治性手术对前列腺癌预后和疗效的Meta分析[J].第三军医大学学报,2011,33(13):1388.
 Wang Jiawu,Jiang Qing,Fan Xiaodong.Prognosis and efficacy of new adjuvant combination endocrine therapy versus radical surgery for prostate cancer: a meta-analysis study[J].J Third Mil Med Univ,2011,33(16):1388.
[3]胡望平,冯福英,叶桂云,等.血清c-PSA及 C/T在提高前列腺癌诊断特异性中的探讨[J].第三军医大学学报,2007,29(18):1815.
 HU Wang-Ping,FENG Fu-ying,YE Gui-yun,et al.Serum complexed-PSA and ratio of complexed/total PSA to improve diagnostic specificity on identifying prostate cancer[J].J Third Mil Med Univ,2007,29(16):1815.
[4]王惠明,王沂芹,阮志华,等.Prostein31-39特异的、HLA-A*2.1限制性NKT细胞表型及功能初步研究[J].第三军医大学学报,2006,28(16):1652.
[5]李云祥,苟欣,何卫阳,等.E2F-3, pRb蛋白在前列腺癌中的表达及其临床意义[J].第三军医大学学报,2006,28(15):1611.
[6]陈勇,江军,张尧,等.含rPB-DR启动子和TK基因的重组腺病毒的构建和鉴定[J].第三军医大学学报,2006,28(10):1043.
[7]吴开杰,张栋,曾津,等.RNAi沉默Smad4基因表达对人前列腺癌细胞增殖的影响[J].第三军医大学学报,2009,31(13):1250.
 WU Kai-jie,ZHANG Dong,ZENG Jin,et al.Effects of Smad4 gene silencing by small interfering RNA on the proliferation of prostate cancer cells in vitro[J].J Third Mil Med Univ,2009,31(16):1250.
[8]张伟杰,马志俊,陆士新,等.前列腺癌组织中DNMT1的表达与GSTP1、APC甲基化状态的关系及临床意义[J].第三军医大学学报,2011,33(15):1602.
 Zhang Weijie,Ma Zhijun,Lu Shixin,et al.Correlation of DNMT1 expression with GSTP1 and APC methylation and its clinical significance[J].J Third Mil Med Univ,2011,33(16):1602.
[9]刁鑫伟,叶明福,张哉根,等.前列腺癌AR表达与细胞增殖的关系[J].第三军医大学学报,2005,27(17):1799.
[10]张尧,江军,王洛夫.前列腺特异性启动子rPB的改造及其载体质粒的构建和活性测定[J].第三军医大学学报,2005,27(10):981.

更新日期/Last Update: 2019-08-22